REVIEW Thalidomide is used for treating multiple myeloma in combination with dexamethasone, erythema nodosum leprosum, and alleviating symptoms of HIV, with strict controls to prevent birth defects. Thalidomide is a potent inhibitor of new blood vessel growth (angiogenesis), which is required for tumor growth.
Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA (2012). A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 118(16):3968-76. PMID 22180010.
Horton MR, Hallowell RW (2012). Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. Drugs Today (Barc). 48(10):661-71. PMID 23110262.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.
WARNING: Attention California residents: This product can expose you to chemicals including Thalidomide, which is known to the State of California to cause birth defects or other reproductive harm. For more information, go to www.P65Warnings.ca.gov.